Towa Pharmaceutical Co., Ltd.
4553.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | ¥145,321,056 | ¥147,238,247 | ¥131,878,820 | ¥165,156,585 |
| - Cash | ¥49,576,000 | ¥35,015,000 | ¥45,471,000 | ¥29,252,000 |
| + Debt | ¥236,263,000 | ¥237,894,000 | ¥232,366,000 | ¥223,479,000 |
| Enterprise Value | ¥332,008,056 | ¥350,117,247 | ¥318,773,820 | ¥359,383,585 |
| Revenue | ¥65,327,000 | ¥65,149,000 | ¥65,857,000 | ¥70,333,000 |
| % Growth | 0.3% | -1.1% | -6.4% | – |
| Gross Profit | ¥23,531,000 | ¥23,675,000 | ¥23,985,000 | ¥25,830,000 |
| % Margin | 36% | 36.3% | 36.4% | 36.7% |
| EBITDA | ¥14,259,000 | ¥10,456,000 | ¥9,320,000 | ¥17,080,000 |
| % Margin | 21.8% | 16% | 14.2% | 24.3% |
| Net Income | ¥5,701,000 | ¥2,513,000 | ¥4,362,000 | ¥8,069,000 |
| % Margin | 8.7% | 3.9% | 6.6% | 11.5% |
| EPS Diluted | 115.81 | 51.05 | 88.61 | 163.92 |
| % Growth | 126.9% | -42.4% | -45.9% | – |
| Operating Cash Flow | ¥8,200,000 | ¥5,892,000 | ¥17,706,000 | -¥2,959,000 |
| Capital Expenditures | -¥8,423,000 | -¥4,380,000 | -¥6,827,000 | -¥10,341,000 |
| Free Cash Flow | -¥223,000 | ¥1,512,000 | ¥10,879,000 | -¥13,300,000 |